{"id":"pentoxifylline","_fda":{"id":"e67bdb49-8c37-8b4f-c982-67d024d3f2aa","set_id":"40ae2d9a-0d95-640d-0640-f76e7e1a13cb","openfda":{"nui":["N0000175895","N0000009065"],"unii":["SD6QCT3TSU"],"route":["ORAL"],"rxcui":["312301"],"spl_id":["e67bdb49-8c37-8b4f-c982-67d024d3f2aa"],"brand_name":["PENTOXIFYLLINE"],"spl_set_id":["40ae2d9a-0d95-640d-0640-f76e7e1a13cb"],"package_ndc":["60505-0033-6","60505-0033-7","60505-0033-9","60505-0033-8"],"product_ndc":["60505-0033"],"generic_name":["PENTOXIFYLLINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Hematologic Activity Alteration [PE]"],"substance_name":["PENTOXIFYLLINE"],"pharm_class_epc":["Blood Viscosity Reducer [EPC]"],"manufacturer_name":["Apotex Corp."],"application_number":["ANDA075191"],"is_original_packager":[true]},"version":"14","pregnancy":["Pregnancy Category C. Teratogenicity studies have been performed in rats and rabbits using oral doses up to 576 and 264 mg/kg, respectively. On a weight basis, these doses are 24 and 11 times the maximum recommended human daily dose (MRHD); on a body-surface-area basis, they are 4.2 and 3.5 times the MRHD. No evidence of fetal malformation was observed. Increased resorption was seen in rats of the 576 mg/kg group. There are no adequate and well controlled studies in pregnant women. Pentoxifylline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Category C. Teratogenicity studies have been performed in rats and rabbits using oral doses up to 576 and 264 mg/kg, respectively. On a weight basis, these doses are 24 and 11 times the maximum recommended human daily dose (MRHD); on a body-surface-area basis, they are 4.2 and 3.5 times the MRHD. No evidence of fetal malformation was observed. Increased resorption was seen in rats of the 576 mg/kg group. There are no adequate and well controlled studies in pregnant women. Pentoxifylline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE Overdosage with pentoxifylline has been reported in pediatric patients and adults. Symptoms appear to be dose related. A report from a poison control center on 44 patients taking overdoses of enteric-coated pentoxifylline extended-release tablets noted that symptoms usually occurred 4 to 5 hours after ingestion and lasted about 12 hours. The highest amount ingested was 80 mg/kg; flushing, hypotension, convulsions, somnolence, loss of consciousness, fever, and agitation occurred. All patients recovered. In addition to symptomatic treatment and gastric lavage, special attention must be given to supporting respiration, maintaining systemic blood pressure, and controlling convulsions. Activated charcoal has been used to absorb pentoxifylline in patients who have overdosed."],"description":["DESCRIPTION Pentoxifylline extended-release tablets, USP for oral administration contain 400 mg of the active drug and the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, and titanium dioxide in an extended-release formulation. Pentoxifylline is a tri-substituted xanthine derivative designated chemically as 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione that, unlike theophylline, is a hemorrheologic agent, i.e., an agent that affects blood viscosity. Pentoxifylline is soluble in water and ethanol, and sparingly soluble in toluene. The molecular formula is C 13 H 18 N 4 O 3 and its molecular weight is 278.31. The chemical structure is: USP Dissolution Test 9"],"precautions":["PRECAUTIONS General At the first sign of anaphylactic/anaphylactoid reaction, pentoxifylline must be discontinued. Patients with chronic occlusive arterial disease of the limbs frequently show other manifestations of arteriosclerotic disease. Pentoxifylline has been used safely for treatment of peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, but there have been occasional reports of angina, hypotension, and arrhythmia. Controlled trials do not show that pentoxifylline causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses. Patients on warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration, cerebral and/or retinal bleeding) should have periodic examinations for bleeding including, hematocrit and/or hemoglobin. In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased. The consequences of the increase in drug exposure are not known (see Pharmacokinetics and Metabolism and DOSAGE AND ADMINISTRATION ). Drug Interactions Bleeding has been reported in patients treated with pentoxifylline with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. Monitoring of anticoagulant activity in these patients is recommended when pentoxifylline is introduced or the dose is changed. Concomitant administration of pentoxifylline and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Monitor theophylline levels when starting pentoxifylline or changing dose. Concomitant administration of strong CYP1A2 inhibitors (including e.g. ciprofloxacin or fluvoxamine) may increase the exposure to pentoxifylline (see ADVERSE REACTIONS ). Pentoxifylline has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced. Postmarketing cases of increased anticoagulant activity have been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. Monitoring of anticoagulant activity in these patients is recommended when pentoxifylline is introduced or the dose is changed. Concomitant administration with cimetidine is reported to increase the average steady state plasma concentration of pentoxifylline (~25%) and the Metabolite I (~30%). Carcinogenesis, Mutagenesis and Impairment of Fertility Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to 450 mg/kg (approximately 19 times the maximum recommended human daily dose (MRHD) in both species when based on body weight; 1.5 times the MRHD in the mouse and 3.3 times the MRHD in the rat when based on body surface area). In mice, the drug was administered for 18 months, whereas in rats, the drug was administered for 18 months followed by an additional 6 months without drug exposure. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females of the 450 mg/kg group. The relevance of this finding to human use is uncertain. Pentoxifylline was devoid of mutagenic activity in various strains of Salmonella (Ames test) and in cultured mammalian cells (unscheduled DNA synthesis test) when tested in the presence and absence of metabolic activation. It was also negative in the in vivo mouse micronucleus test. Pregnancy Category C. Teratogenicity studies have been performed in rats and rabbits using oral doses up to 576 and 264 mg/kg, respectively. On a weight basis, these doses are 24 and 11 times the maximum recommended human daily dose (MRHD); on a body-surface-area basis, they are 4.2 and 3.5 times the MRHD. No evidence of fetal malformation was observed. Increased resorption was seen in rats of the 576 mg/kg group. There are no adequate and well controlled studies in pregnant women. Pentoxifylline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Pentoxifylline and its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for pentoxifylline in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of pentoxifylline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The active metabolite V is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"how_supplied":["HOW SUPPLIED Pentoxifylline extended-release tablets, USP are available for oral administration as 400 mg white, oval, unscored, film coated tablets, imprinted “APO 033” on one side and plain on the other side; supplied in bottles of 100 (NDC 60505-0033-6), bottles of 500 (NDC 60505-0033-7), bottles of 1,000 (NDC 60505-0033-9) and bottles of 5,500 (NDC 60505-0033-8). Store at 20° to 25°C (68° to 77°F) [see Controlled Room Temperature]. Dispense in a tight, light-resistant container [see USP]. APOTEX INC. PENTOXIFYLLINE EXTENDED-RELEASE TABLETS, USP 400mg Manufactured by Manufactured for Apotex Inc. Apotex Corp. Toronto, Ontario Weston, Florida Canada M9L 1T9 33326 Revised: May 2016 Rev. 7"],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20250821","nursing_mothers":["Nursing Mothers Pentoxifylline and its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for pentoxifylline in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS Clinical trials were conducted using either extended-release pentoxifylline tablets for up to 60 weeks or immediate-release pentoxifylline capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200 to 400 mg tid. The table summarizes the incidence (in percent) of adverse reactions considered drug related, as well as the numbers of patients who received extended-release pentoxifylline tablets, immediate-release pentoxifylline capsules, or the corresponding placebos. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the extended-release tablets were conducted outside the U.S. The table indicates that in the tablet studies few patients discontinued because of adverse effects. INCIDENCE (%) OF SIDE EFFECTS Extended-Release Tables Immediate-Release Capsules Commercially Available Used Only For Controlled Clinical Trials Pentoxifylline Placebo Pentoxifylline Placebo (Number of Patients at Risk) (321) (128) (177) (138) Discontinued for Side Effect 3.1 0 9.6 7.2 CARDIOVASCULAR SYSTEM Angina/Chest Pain 0.3 - 1.1 2.2 Arrhythmia/Palpitation - - 1.7 0.7 Flushing - - 2.3 0.7 DIGESTIVE SYSTEM Abdominal Discomfort - - 4.0 1.4 Belching/Flatus/Bloating 0.6 - 9.0 3.6 Diarrhea - - 3.4 2.9 Dyspepsia 2.8 4.7 9.6 2.9 Nausea 2.2 0.8 28.8 8.7 Vomiting 1.2 - 4.5 0.7 NERVOUS SYSTEM Agitation/Nervousness - - 1.7 0.7 Dizziness 1.9 3.1 11.9 4.3 Drowsiness - - 1.1 5.8 Headache 1.2 1.6 6.2 5.8 Insomnia - - 2.3 2.2 Tremor 0.3 0.8 - - Blurred Vision - - 2.3 1.4 Pentoxifylline has been marketed in Europe and elsewhere since 1972. In addition to the above symptoms, the following have been reported spontaneously since marketing or occurred in other clinical trials with an incidence of less than 1%; the causal relationship was uncertain: Cardiovascular - dyspnea, edema, hypotension. Digestive - anorexia, cholecystitis, constipation, dry mouth/thirst. Nervous - anxiety, confusion, depression, seizures, aseptic meningitis. Respiratory - epistaxis, flu-like symptoms, laryngitis, nasal congestion. Skin and Appendages - brittle fingernails, pruritus, rash, urticaria, angioedema. Special Senses - blurred vision, conjunctivitis, earache, scotoma. Miscellaneous - bad taste, excessive salivation, leukopenia, malaise, sore throat/swollen neck glands, weight change. A few rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians. Cardiovascular - angina, arrhythmia, tachycardia. Digestive - hepatitis, jaundice, cholestasis, increased liver enzymes; and Hemic and Lymphatic - decreased serum fibrinogen, pancytopenia, aplastic anemia, leukemia, purpura, thrombocytopenia. Immune system disorders - anaphylactic reaction, anaphylactoid reaction, anaphylactic shock."],"contraindications":["CONTRAINDICATIONS Pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine."],"drug_interactions":["Drug Interactions Bleeding has been reported in patients treated with pentoxifylline with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. Monitoring of anticoagulant activity in these patients is recommended when pentoxifylline is introduced or the dose is changed. Concomitant administration of pentoxifylline and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Monitor theophylline levels when starting pentoxifylline or changing dose. Concomitant administration of strong CYP1A2 inhibitors (including e.g. ciprofloxacin or fluvoxamine) may increase the exposure to pentoxifylline (see ADVERSE REACTIONS ). Pentoxifylline has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced. Postmarketing cases of increased anticoagulant activity have been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. Monitoring of anticoagulant activity in these patients is recommended when pentoxifylline is introduced or the dose is changed. Concomitant administration with cimetidine is reported to increase the average steady state plasma concentration of pentoxifylline (~25%) and the Metabolite I (~30%)."],"general_precautions":["General At the first sign of anaphylactic/anaphylactoid reaction, pentoxifylline must be discontinued. Patients with chronic occlusive arterial disease of the limbs frequently show other manifestations of arteriosclerotic disease. Pentoxifylline has been used safely for treatment of peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, but there have been occasional reports of angina, hypotension, and arrhythmia. Controlled trials do not show that pentoxifylline causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses. Patients on warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration, cerebral and/or retinal bleeding) should have periodic examinations for bleeding including, hematocrit and/or hemoglobin. In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased. The consequences of the increase in drug exposure are not known (see Pharmacokinetics and Metabolism and DOSAGE AND ADMINISTRATION )."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mode of Action Pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise mode of action of pentoxifylline and the sequence of events leading to clinical improvement are still to be defined. Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility. Leukocyte properties of hemorrheologic importance have been modified in animal and in vitro human studies. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation. Tissue oxygen levels have been shown to be significantly increased by therapeutic doses of pentoxifylline in patients with peripheral arterial disease. Pharmacokinetics and Metabolism After oral administration in aqueous solution pentoxifylline is almost completely absorbed. It undergoes a first-pass effect and the various metabolites appear in plasma very soon after dosing. Peak plasma levels of the parent compound and its metabolites are reached within 1 hour. The major metabolites are Metabolite I (1-[5-hydroxyhexyl]-3,7-dimethylxanthine) and Metabolite V (1-[3-carboxypropyl]-3,7-dimethylxanthine), and plasma levels of these metabolites are 5 and 8 times greater, respectively, than pentoxifylline. Following oral administration of aqueous solutions containing 100 to 400 mg of pentoxifylline, the pharmacokinetics of the parent compound and Metabolite I are dose-related and not proportional (non-linear), with half-life and area under the blood-level time curve (AUC) increasing with dose. The elimination kinetics of Metabolite V are not dose-dependent. The apparent plasma half-life of pentoxifylline varies from 0.4 to 0.8 hours and the apparent plasma half-lives of its metabolites vary from 1 to 1.6 hours. There is no evidence of accumulation or enzyme induction (Cytochrome P450) following multiple oral doses. Excretion is almost totally urinary; the main biotransformation product is Metabolite V. Essentially no parent drug is found in the urine. Despite large variations in plasma levels of parent compound and its metabolites, the urinary recovery of Metabolite V is consistent and shows dose proportionality. Less than 4% of the administered dose is recovered in feces. Food intake shortly before dosing delays absorption of an immediate-release dosage form but does not affect total absorption. The pentoxifylline AUC was increased and elimination rate decreased in an older population (60 to 68 years, n=6) compared to younger individuals (22 to 30 years, n=6) (see PRECAUTIONS , Geriatric Use ). After administration of the 400 mg extended-release pentoxifylline tablet, plasma levels of the parent compound and its metabolites reach their maximum within 2 to 4 hours and remain constant over an extended period of time. Coadministration of pentoxifylline extended-release tablets with meals resulted in an increase in mean AUC and C max of about 1.1 and 1.3 fold for pentoxifylline, respectively. C max for Metabolite I also increased about 1.2 fold. The extended release of pentoxifylline from the tablet eliminates peaks and troughs in plasma levels for improved gastrointestinal tolerance. Patients with Hepatic Impairment In patients with mild to moderate liver impairment AUC and C max of pentoxifylline increased 6.5 and 7.5 fold, respectively, after a single 400 mg dose of pentoxifylline extended-release tablet AUC and C max of the active Metabolite I also increased 6.9 and 8.2 fold, respectively, in hepatic impaired subjects. Pentoxifylline extended-release tablet has not been studied in patients with severe hepatic failure. Patients with Renal Impairment In patients with mild, moderate, or severe renal impairment the exposure to pentoxifylline and its active Metabolite I are not increased. In contrast, AUC 0-tss and C max of the active Metabolite V in patients with mild to moderate renal impairment increased 2.4 and 2.1 fold, respectively, with a 400 mg TID regimen of pentoxifylline extended-release tablet. In severe renal impairment AUC 0 to tss and C max of the active Metabolite V increased 12.9 and 10.6 fold, respectively, with a 400 mg pentoxifylline extended-release tablet TID regimen. The increase in exposure to Metabolite V is only slightly smaller in both renal impairment groups if pentoxifylline extended-release tablet is administered BID."],"indications_and_usage":["INDICATIONS AND USAGE Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."],"adverse_reactions_table":["
INCIDENCE (%) OF SIDE EFFECTS
Extended-Release Tables Immediate-Release Capsules
Commercially AvailableUsed Only For Controlled Clinical Trials
Pentoxifylline PlaceboPentoxifylline Placebo
(Number of Patients at Risk)(321)(128)(177)(138)
Discontinued for Side Effect3.109.67.2
CARDIOVASCULAR SYSTEM
Angina/Chest Pain0.3-1.12.2
Arrhythmia/Palpitation--1.70.7
Flushing--2.30.7
DIGESTIVE SYSTEM
Abdominal Discomfort--4.01.4
Belching/Flatus/Bloating0.6-9.03.6
Diarrhea--3.42.9
Dyspepsia2.84.79.62.9
Nausea2.20.828.88.7
Vomiting1.2-4.50.7
NERVOUS SYSTEM
Agitation/Nervousness--1.70.7
Dizziness1.93.111.94.3
Drowsiness--1.15.8
Headache1.21.66.25.8
Insomnia--2.32.2
Tremor0.30.8--
Blurred Vision--2.31.4
"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The usual dosage of pentoxifylline in extended-release tablet form is one tablet (400 mg) three times a day with meals. While the effect of pentoxifylline may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration. Digestive and central nervous system side effects are dose related. If patients develop these effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of pentoxifylline should be discontinued. In patients with severe renal impairment (creatinine clearance below 30 mL/min) reduce dose to 400 mg once a day. Dosing information cannot be provided for patients with hepatic impairment."],"spl_product_data_elements":["PENTOXIFYLLINE PENTOXIFYLLINE PENTOXIFYLLINE PENTOXIFYLLINE SILICON DIOXIDE HYDROXYPROPYL CELLULOSE (1600000 WAMW) HYPROMELLOSE, UNSPECIFIED MAGNESIUM STEARATE POLYETHYLENE GLYCOL 8000 TITANIUM DIOXIDE APO;033 structure 400mg-100btl.jpg"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 400 mg BOTTLE APOTEX CORP. NDC 60505-0033-6 Pentoxifylline Extended-Release Tablets, USP 400 mg Rx 100 count"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis and Impairment of Fertility Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to 450 mg/kg (approximately 19 times the maximum recommended human daily dose (MRHD) in both species when based on body weight; 1.5 times the MRHD in the mouse and 3.3 times the MRHD in the rat when based on body surface area). In mice, the drug was administered for 18 months, whereas in rats, the drug was administered for 18 months followed by an additional 6 months without drug exposure. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females of the 450 mg/kg group. The relevance of this finding to human use is uncertain. Pentoxifylline was devoid of mutagenic activity in various strains of Salmonella (Ames test) and in cultured mammalian cells (unscheduled DNA synthesis test) when tested in the presence and absence of metabolic activation. It was also negative in the in vivo mouse micronucleus test."]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"NSAIDs, anticoagulants, or platelet aggregation inhibitors","severity":"major","mechanism":"Not specified","management":"Monitor for signs of bleeding","clinicalEffect":"Bleeding"},{"drug":"vitamin K antagonists","severity":"major","mechanism":"Increased prothrombin time","management":"Monitor anticoagulant activity when pentoxifylline is introduced or the dose is changed","clinicalEffect":"Increased anticoagulant activity"},{"drug":"theophylline-containing drugs","severity":"major","mechanism":"Increased theophylline levels","management":"Monitor theophylline levels when starting pentoxifylline or changing dose","clinicalEffect":"Theophylline toxicity"},{"drug":"strong CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine)","severity":"moderate","mechanism":"Increased exposure to pentoxifylline","management":"Monitor for adverse reactions","clinicalEffect":"Potential for increased adverse reactions"},{"drug":"antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics","severity":"minor","mechanism":"Not specified","management":"No specific management required","clinicalEffect":"No observed problems"},{"drug":"nifedipine or captopril","severity":"moderate","mechanism":"Small decreases in blood pressure","management":"Periodic systemic blood pressure monitoring; reduce antihypertensive agent dosage if indicated","clinicalEffect":"Hypotension"},{"drug":"cimetidine","severity":"moderate","mechanism":"Increased average steady state plasma concentration of pentoxifylline and Metabolite I","management":"Monitor for adverse reactions","clinicalEffect":"Increased exposure to pentoxifylline and its metabolites"}],"commonSideEffects":[{"effect":"Discontinued for Side Effect","drugRate":"3.1","_validated":true,"placeboRate":"0"},{"effect":"Angina/Chest Pain","drugRate":"0.3","_validated":true,"placeboRate":""},{"effect":"Belching/Flatus/Bloating","drugRate":"0.6","_validated":true,"placeboRate":""},{"effect":"Dyspepsia","drugRate":"2.8","_validated":true,"placeboRate":"4.7"},{"effect":"Nausea","drugRate":"2.2","_validated":true,"placeboRate":"0.8"},{"effect":"Vomiting","drugRate":"1.2","_validated":true,"placeboRate":""},{"effect":"Dizziness","drugRate":"1.9","_validated":true,"placeboRate":"3.1"},{"effect":"Headache","drugRate":"1.2","_validated":true,"placeboRate":"1.6"},{"effect":"Tremor","drugRate":"0.3","_validated":true,"placeboRate":"0.8"},{"effect":"Discontinued for Side Effect","drugRate":"9.6","_validated":true,"placeboRate":"7.2"},{"effect":"Angina/Chest Pain","drugRate":"1.1","_validated":true,"placeboRate":"2.2"},{"effect":"Arrhythmia/Palpitation","drugRate":"1.7","_validated":true,"placeboRate":"0.7"},{"effect":"Flushing","drugRate":"2.3","_validated":true,"placeboRate":"0.7"},{"effect":"Abdominal Discomfort","drugRate":"4.0","_validated":true,"placeboRate":"1.4"},{"effect":"Belching/Flatus/Bloating","drugRate":"9.0","_validated":true,"placeboRate":"3.6"},{"effect":"Diarrhea","drugRate":"3.4","_validated":true,"placeboRate":"2.9"},{"effect":"Dyspepsia","drugRate":"9.6","_validated":true,"placeboRate":"2.9"},{"effect":"Nausea","drugRate":"28.8","_validated":true,"placeboRate":"8.7"},{"effect":"Vomiting","drugRate":"4.5","_validated":true,"placeboRate":"0.7"},{"effect":"Agitation/Nervousness","drugRate":"1.7","_validated":true,"placeboRate":"0.7"},{"effect":"Dizziness","drugRate":"11.9","_validated":true,"placeboRate":"4.3"},{"effect":"Drowsiness","drugRate":"1.1","_validated":true,"placeboRate":"5.8"},{"effect":"Headache","drugRate":"6.2","_validated":true,"placeboRate":"5.8"},{"effect":"Insomnia","drugRate":"2.3","_validated":true,"placeboRate":"2.2"},{"effect":"Blurred Vision","drugRate":"2.3","_validated":true,"placeboRate":"1.4"}],"contraindications":["Pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage.","Pentoxifylline should not be used in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine."],"discontinuationRates":[{"trial":"Extended-Release Tablets","drugArm":"3.1","placeboArm":"0","commonReason":""},{"trial":"Immediate-Release Capsules","drugArm":"9.6","placeboArm":"7.2","commonReason":""}]},"_chembl":null,"patents":[],"_fixedAt":"2026-03-30T11:49:26.934568","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PENTOXIFYLLINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:36:29.358089+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:38:08.001723+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:36:34.826371+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PENTOXIFYLLINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:36:35.213094+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:36:28.245679+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:36:28.245705+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:38:03.563183+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:36:28.245710+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: 3',5'-cyclic phosphodiesterase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:36:36.331717+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:37:57.594548+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL628/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:36:35.990345+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Clinical trials were conducted using either extended-release pentoxifylline tablets for up to 60 weeks or immediate-release pentoxifylline capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200 to 400 mg tid. The table summarizes the incidence (in percent) of adverse reactions considered drug related, as well as the numbers of patients who received extended-release pentoxifylline tablets, immediate-release pentoxi","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:37:24.630470+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:37:29.291106+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075191","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:36:28.245713+00:00"}},"_dailymed":{"setId":"08b095b6-be53-41f5-a284-fe15d4852f79","title":"PENTOXIFYLLINE POWDER [AX PHARMACEUTICAL CORP]"},"aiSummary":"Pentoxifylline is a marketed drug primarily indicated for the treatment of intermittent claudication. Its key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market position. The primary risk is the potential increase in competition following patent expiry in 2028.","mechanism":{"modality":"Small Molecule","drugClass":"Blood Viscosity Reducer [EPC]"},"_scrapedAt":"2026-03-27T23:35:50.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:38:08.002097+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"pentoxifylline-intermittent-claudication","name":"Intermittent Claudication","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with intermittent claudication due to chronic occlusive arterial disease of the limbs","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with intermittent claudication due to chronic occlusive arterial disease of the limbs","diagnosticRequired":null,"brandNameForIndication":""}]},"_fixedFields":["sideEffects","generics(8)","patents(0)","modality→Small Molecule"],"patentStatus":"Off-patent — no active Orange Book patents","trialDetails":[{"nctId":"NCT06634056","phase":"PHASE2","title":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-05-30","conditions":"Non-Small Cell Lung Cancer, Radiation Induced Lung Injury (RILI)","enrollment":150},{"nctId":"NCT03723291","phase":"PHASE1","title":"PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University College, London","startDate":"2019-09-01","conditions":"Head and Neck Fibrosis","enrollment":50},{"nctId":"NCT05513560","phase":"PHASE2, PHASE3","title":"RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2023-05-31","conditions":"Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19","enrollment":460},{"nctId":"NCT07043335","phase":"NA","title":"Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis","status":"RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2025-07-01","conditions":"Lateral Epicondylitis, Tennis Elbow","enrollment":50},{"nctId":"NCT06494111","phase":"PHASE2","title":"Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-13","conditions":"Lymphedema, Fibrosis","enrollment":295},{"nctId":"NCT05640817","phase":"NA","title":"Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-01-10","conditions":"Pentoxifylline, Cisplatin, Nephrotoxixcity","enrollment":90},{"nctId":"NCT06912763","phase":"PHASE2","title":"Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-08-08","conditions":"Fibrosis Syndrome, Lymphedema, Head &Amp; Neck Cancer","enrollment":250},{"nctId":"NCT07349472","phase":"PHASE2","title":"Pentoxifylline in Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-01-20","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT07315139","phase":"NA","title":"Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-01","conditions":"Pentoxifylline, Inflammatory Markers, Non-Diabetic","enrollment":42},{"nctId":"NCT03625648","phase":"PHASE4","title":"Pentoxifylline in Diabetic Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-11-18","conditions":"Diabetic Kidney Disease","enrollment":2376},{"nctId":"NCT07252518","phase":"NA","title":"Effect of Pentoxifylline + CoQ10 vs CoQ10 Alone on Sperm Motility in Subfertile Men With Asthenozoospermia","status":"RECRUITING","sponsor":"Mst.Sumyara Khatun","startDate":"2025-10-01","conditions":"Asthenozoospermia","enrollment":56},{"nctId":"NCT07086794","phase":"EARLY_PHASE1","title":"Cocaine and Pentoxifylline (BED IN 47)","status":"RECRUITING","sponsor":"William Stoops","startDate":"2025-11-10","conditions":"Cocaine Use Disorder","enrollment":30},{"nctId":"NCT06055257","phase":"PHASE3","title":"Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-01-16","conditions":"Osteoradionecrosis, Osteoradionecrosis of Jaw, Osteoradionecrosis of the Mandible","enrollment":24},{"nctId":"NCT06998628","phase":"PHASE2","title":"Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-06-02","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT07137793","phase":"PHASE2","title":"Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-25","conditions":"Doxorubicin Induced Cardiotoxicity, Breast Cancer","enrollment":46},{"nctId":"NCT05962957","phase":"PHASE2","title":"Role of Pentoxifylline and Celecoxib in Parkinsonism","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-07","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT05635370","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Peripheral Artery Disease","enrollment":10398},{"nctId":"NCT05558761","phase":"PHASE2","title":"Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-10","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT06944704","phase":"PHASE2","title":"Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-04-03","conditions":"Hepatobiliary Disorders","enrollment":43},{"nctId":"NCT06186700","phase":"PHASE2","title":"Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2023-12-25","conditions":"Breast Cancer Female, Breast Cancer Patients, Neoadjuvant Therapy","enrollment":100},{"nctId":"NCT07088328","phase":"NA","title":"Nephroprotection Following Perinatal Asphyxia: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-07-30","conditions":"Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy, Pentoxifylline Adverse Reaction","enrollment":30},{"nctId":"NCT07085806","phase":"NA","title":"To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-01-01","conditions":"Liver Regeneration","enrollment":60},{"nctId":"NCT06087237","phase":"PHASE2","title":"The Efficacy of Using Pentoxifylline in Patients Undergoing Breast Cancer Surgery","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2023-10-30","conditions":"Post-Surgical Complication, Breast Cancer Surgery","enrollment":92},{"nctId":"NCT07017114","phase":"PHASE1","title":"Pentoxifylline PKB171 Gel in Healthy Females Volunteers","status":"COMPLETED","sponsor":"Prokrea BCN, S.L.","startDate":"2016-01-27","conditions":"Safety, Pharmacokinetics, Maximum Tolerated Dose","enrollment":30},{"nctId":"NCT06265389","phase":"PHASE4","title":"Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-03-01","conditions":"Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia","enrollment":100},{"nctId":"NCT05284656","phase":"PHASE3","title":"Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Azhar University","startDate":"2022-01-08","conditions":"Chronic Kidney Diseases","enrollment":80},{"nctId":"NCT04391231","phase":"PHASE4","title":"HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-06-01","conditions":"Hemolysis Intravascular, Acute Decompensated Heart Failure","enrollment":""},{"nctId":"NCT06458465","phase":"NA","title":"Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2023-10-01","conditions":"Chronic Kidney Disease","enrollment":60},{"nctId":"NCT06986031","phase":"PHASE2","title":"PKB171 Against Placebo in Couples With Asthenozoospermia Who Wish to Conceive","status":"TERMINATED","sponsor":"Prokrea BCN, S.L.","startDate":"2017-05-08","conditions":"Infertility, Male","enrollment":60},{"nctId":"NCT03060434","phase":"PHASE4","title":"Pentoxifylline and Lumbar Radiculopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St Joseph University, Beirut, Lebanon","startDate":"2018-06-01","conditions":"Lumbar Radiculopathy, Lumbar Disc Herniation, Lumbar Disc Disease","enrollment":67},{"nctId":"NCT06332612","phase":"PHASE1, PHASE2","title":"Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2024-08-12","conditions":"Oral Submucous Fibrosis","enrollment":30},{"nctId":"NCT06538194","phase":"NA","title":"Comparison of the Efficacy of Dextrose Prolotherapy and Mesotherapy in Lateral Epicondylitis","status":"COMPLETED","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2024-04-01","conditions":"Lateral Epicondylitis","enrollment":84},{"nctId":"NCT06903689","phase":"PHASE1, PHASE2","title":"Pentoxifylline for Vascular Calcification in Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Chronic Kidney Disease, Vascular Calcification, Kidney Failure, Chronic","enrollment":80},{"nctId":"NCT05575505","phase":"PHASE2","title":"Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-02-02","conditions":"Inflammatory Bowel Diseases","enrollment":44},{"nctId":"NCT06823362","phase":"PHASE4","title":"Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions","status":"NOT_YET_RECRUITING","sponsor":"Centro de Atencion e Investigacion Medica","startDate":"2025-04-10","conditions":"Healthy, Healthy Donors","enrollment":40},{"nctId":"NCT02592863","phase":"NA","title":"Trental for the Treatment of Vertigo/Dizziness/Imbalance","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2015-01","conditions":"Dizziness, Vertigo","enrollment":26},{"nctId":"NCT04696354","phase":"NA","title":"Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)","status":"TERMINATED","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2021-10-12","conditions":"Venous Ulcer of Leg","enrollment":12},{"nctId":"NCT05897372","phase":"PHASE2","title":"Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study","status":"TERMINATED","sponsor":"Iain Bressendorff","startDate":"2023-08-01","conditions":"Diabetic Kidney Disease","enrollment":1},{"nctId":"NCT06562998","phase":"NA","title":"Pentoxifylline Role Against Chemotherapy-induced Neuropathy","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2022-07-01","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":72},{"nctId":"NCT04152980","phase":"PHASE3","title":"Pentoxifylline Dose Optimization in Neonatal Sepsis","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2020-01-12","conditions":"Neonatal Late Onset Sepsis","enrollment":30},{"nctId":"NCT05637086","phase":"PHASE2","title":"Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2022-12-20","conditions":"Epilepsy","enrollment":90},{"nctId":"NCT05284448","phase":"PHASE3","title":"Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2022-02-01","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":50},{"nctId":"NCT03040778","phase":"PHASE3","title":"Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)","status":"ENROLLING_BY_INVITATION","sponsor":"University of Washington","startDate":"2018-04-01","conditions":"Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis","enrollment":100},{"nctId":"NCT06421870","phase":"PHASE3","title":"Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-03-01","conditions":"Chronic Kidney Diseases","enrollment":210},{"nctId":"NCT06422000","phase":"PHASE3","title":"Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-06-30","conditions":"Necrotizing Enterocolitis","enrollment":75},{"nctId":"NCT05487755","phase":"PHASE3","title":"Investigational and Comparative Study in the Management of Diabetic Nephropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-02-01","conditions":"Diabetic Nephropathy Type 2","enrollment":90},{"nctId":"NCT06409546","phase":"NA","title":"Impact of Topical Pentoxifylline and Tocopherol in Treatment and Prevention of Medically-related Osteonecrosis of the Jaws","status":"COMPLETED","sponsor":"University of Catania","startDate":"2020-04-02","conditions":"Medically Related Osteonecrosis of the Jaws","enrollment":48},{"nctId":"NCT06344390","phase":"PHASE1, PHASE2","title":"Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke","status":"RECRUITING","sponsor":"The First Hospital of Hebei Medical University","startDate":"2024-04-10","conditions":"Cognitive Impairment","enrollment":200},{"nctId":"NCT06319768","phase":"NA","title":"Efficacy of Intralesional Injection of Pentoxifylline, Platelet-Rich Plasma, and Combined Pentoxifylline With Platelet-Rich Plasma in Patients With Atrophic Acne Scars","status":"RECRUITING","sponsor":"Sohag University","startDate":"2024-01-01","conditions":"Atrophic Acne Scar","enrollment":75},{"nctId":"NCT02932501","phase":"","title":"Medication-related Osteonecrosis of the Jaw (MRONJ) Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"AO Clinical Investigation and Publishing Documentation","startDate":"2017-08-14","conditions":"Medication-related Osteonecrosis of the Jaw, Bisphosphonate-Associated Osteonecrosis of the Jaw","enrollment":518},{"nctId":"NCT06176339","phase":"PHASE2","title":"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mansoura University","startDate":"2023-12-15","conditions":"Breast Cancer Female","enrollment":70},{"nctId":"NCT05795647","phase":"PHASE2","title":"The PENTO Protocol in Medication-related Osteonecrosis of the Jaw","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2024-02-29","conditions":"Medication-related Osteonecrosis of the Jaw (MRONJ)","enrollment":17},{"nctId":"NCT01871454","phase":"PHASE2","title":"Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers","status":"UNKNOWN","sponsor":"University of Louisville","startDate":"2013-10","conditions":"Non-small Cell Lung Cancers","enrollment":59},{"nctId":"NCT05189535","phase":"PHASE2, PHASE3","title":"\"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients\"","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-10-03","conditions":"Breast Cancer Female, Peripheral Neuropathy","enrollment":66},{"nctId":"NCT02530697","phase":"PHASE2","title":"The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Brasilia","startDate":"2015-08","conditions":"Leishmaniasis","enrollment":160},{"nctId":"NCT01774487","phase":"PHASE2","title":"Pentoxifylline Therapy in Biliary Atresia","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2013-02-04","conditions":"Biliary Atresia","enrollment":17},{"nctId":"NCT05611268","phase":"NA","title":"Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2022-06-03","conditions":"Eisenmenger Syndrome","enrollment":48},{"nctId":"NCT05190588","phase":"NA","title":"Efficacy of Mesotherapy in Patients With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2022-04-27","conditions":"Knee Osteoarthritis","enrollment":40},{"nctId":"NCT06115174","phase":"PHASE4","title":"Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-11-01","conditions":"Metastatic Colorectal Carcinoma","enrollment":44},{"nctId":"NCT06087796","phase":"PHASE1","title":"Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-10","conditions":"Alopecia Areata","enrollment":60},{"nctId":"NCT03830164","phase":"PHASE2","title":"Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-11-20","conditions":"Male Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE","enrollment":14},{"nctId":"NCT03916068","phase":"PHASE2","title":"Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy","status":"TERMINATED","sponsor":"Legacy Health System","startDate":"2019-07-01","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT06041932","phase":"NA","title":"Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-11-01","conditions":"Liver Cirrhosis","enrollment":180},{"nctId":"NCT06040489","phase":"PHASE2, PHASE3","title":"Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly","status":"RECRUITING","sponsor":"University of Brasilia","startDate":"2022-06-22","conditions":"Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous","enrollment":100},{"nctId":"NCT01508221","phase":"PHASE2","title":"Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2011-06","conditions":"Brain Metastasis","enrollment":31},{"nctId":"NCT03888846","phase":"PHASE2","title":"Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers","status":"COMPLETED","sponsor":"Ipekyolu Ilac Ltd. Sti","startDate":"2019-03-25","conditions":"Behçet Disease Affecting Oral Mucosa","enrollment":41},{"nctId":"NCT05971667","phase":"PHASE2, PHASE3","title":"Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-30","conditions":"IVF","enrollment":200},{"nctId":"NCT04186559","phase":"PHASE2","title":"Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers","status":"UNKNOWN","sponsor":"Silk Road Therapies, Inc.","startDate":"2024-02","conditions":"Behcet Syndrome, Behcet Disease","enrollment":60},{"nctId":"NCT05231980","phase":"PHASE2","title":"Efficacy of Pentoxifylline and Alpha Lipoic Acid in PCOS Resistant to Clomiphene Citrate","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-06-05","conditions":"Clomiphene Citrate, Resistant Ovary Syndrome, Polycystic Ovary Syndrome","enrollment":120},{"nctId":"NCT05943353","phase":"NA","title":"ICSI Using Pentoxifylline to Identify Viable Spermatozoa in Absolute Asthenozoospermia Patients","status":"UNKNOWN","sponsor":"Mỹ Đức Hospital","startDate":"2023-08","conditions":"in Vitro Fertilization","enrollment":10},{"nctId":"NCT05387187","phase":"PHASE2, PHASE3","title":"Evaluate the Effect and Safety of Pu Yang Wan Wu Tang and Western Medicine on Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Taipei Medical University Hospital","startDate":"2022-05-01","conditions":"Chronic Kidney Diseases","enrollment":40},{"nctId":"NCT05897034","phase":"PHASE2, PHASE3","title":"Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2023-06-20","conditions":"Sexually Transmitted Diseases","enrollment":100},{"nctId":"NCT05490953","phase":"PHASE4","title":"Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2022-07-11","conditions":"Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT04739345","phase":"NA","title":"Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Covid19, Corona Virus Infection, Cytokine Storm","enrollment":69},{"nctId":"NCT05708248","phase":"NA","title":"Effect of Pentoxifylline on Anemia in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2023-02","conditions":"Hemodialysis Complication","enrollment":80},{"nctId":"NCT00003407","phase":"PHASE2","title":"Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2001-02-13","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT04433988","phase":"PHASE1, PHASE2","title":"Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2022-11-13","conditions":"COVID","enrollment":""},{"nctId":"NCT05660694","phase":"PHASE4","title":"Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis","status":"COMPLETED","sponsor":"Altamash Institute of Dental Medicine","startDate":"2020-01-01","conditions":"Triamcinolone, Pentoxifylline, Vitamin E","enrollment":40},{"nctId":"NCT04910178","phase":"PHASE4","title":"Follow-up of NAFLD Patients With MRI-PDFF","status":"COMPLETED","sponsor":"Asmaa Abdelfattah Elsayed","startDate":"2020-12-01","conditions":"Diabetes Type 2, NAFLD","enrollment":80},{"nctId":"NCT05329116","phase":"NA","title":"Efficacy of Mesotherapy Added to Intra-articular Platelet-rich Plasma (PRP) in Patients With Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Necmettin Yildiz","startDate":"2022-05-15","conditions":"Osteo Arthritis Knee","enrollment":42},{"nctId":"NCT04094207","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-01-01","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT05590117","phase":"EARLY_PHASE1","title":"Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-10-11","conditions":"Colo-rectal Cancer, Neuropathy;Peripheral, Mucositis","enrollment":48},{"nctId":"NCT05583266","phase":"PHASE4","title":"Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2022-11-01","conditions":"Cerebral Small Vessel Diseases","enrollment":80},{"nctId":"NCT05324735","phase":"PHASE1, PHASE2","title":"Pentoxifylline for Treatment of Resistant Major Depression","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2021-12-15","conditions":"Resistant Major Depression","enrollment":60},{"nctId":"NCT05271084","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2021-11-10","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT04367935","phase":"PHASE2, PHASE3","title":"Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-01-01","conditions":"Acute Coronary Syndrome","enrollment":43},{"nctId":"NCT05502952","phase":"NA","title":"Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-07-27","conditions":"Alopecia Areata","enrollment":50},{"nctId":"NCT01337349","phase":"NA","title":"Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2010-07","conditions":"Congestive Heart Failure","enrollment":""},{"nctId":"NCT05373134","phase":"NA","title":"Efficacy and Safety of Pentoxifylline in Improving Oxygenation in Hepatopulmonary Syndrome","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-05-05","conditions":"Hepatopulmonary Syndrome","enrollment":40},{"nctId":"NCT04417049","phase":"EARLY_PHASE1","title":"Treatment of Bipolar Depression With Pentoxifylline","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-07-12","conditions":"Bipolar Depression","enrollment":6},{"nctId":"NCT05178953","phase":"EARLY_PHASE1","title":"The Therapeutic Effect of Co-administration of Pentoxifylline and Zinc in Men With Idiopathic Asthenozoospermia","status":"UNKNOWN","sponsor":"Arak University of Medical Sciences","startDate":"2021-08-01","conditions":"Men Infertility","enrollment":160},{"nctId":"NCT05156684","phase":"NA","title":"Effect of Pentoxifylline and Zinc Co-administration in Patients With Oligoasthenoteratozoospermia","status":"UNKNOWN","sponsor":"Arak University of Medical Sciences","startDate":"2022-01-01","conditions":"Idiopathic Infertility","enrollment":140},{"nctId":"NCT05152511","phase":"","title":"Management of Post-circumcision Ischemia Using Hyperbaric Oxygen Therapy","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2017-04-01","conditions":"Post-circumsion Complications","enrollment":23},{"nctId":"NCT00000646","phase":"PHASE1","title":"Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01809132","phase":"PHASE2, PHASE3","title":"Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Mack Mitchell","startDate":"2013-09","conditions":"Acute Alcoholic Hepatitis","enrollment":104},{"nctId":"NCT03342950","phase":"PHASE2","title":"The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain","status":"TERMINATED","sponsor":"Terence J. Coderre","startDate":"2019-02-19","conditions":"Neuralgia Peripheral","enrollment":4},{"nctId":"NCT05073640","phase":"PHASE1, PHASE2","title":"Pentoxifylline Add-on Therapy for Schizophrenia","status":"UNKNOWN","sponsor":"Mazra Mental Health Center","startDate":"2019-04-20","conditions":"Schizophrenia","enrollment":90},{"nctId":"NCT02776059","phase":"PHASE2","title":"Pegfilgrastim in Patients With Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2017-01-21","conditions":"Alcoholic Hepatitis","enrollment":34},{"nctId":"NCT04977661","phase":"PHASE4","title":"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2020-02-01","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":102},{"nctId":"NCT04570254","phase":"NA","title":"Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19","status":"COMPLETED","sponsor":"Unidad Temporal COVID-19 en Centro Citibanamex","startDate":"2020-08-19","conditions":"Pneumonia, Viral, Covid19, ARDS","enrollment":110}],"_emaApprovals":[],"_faersSignals":[{"count":455,"reaction":"FATIGUE"},{"count":447,"reaction":"DIARRHOEA"},{"count":410,"reaction":"DYSPNOEA"},{"count":400,"reaction":"DRUG INEFFECTIVE"},{"count":383,"reaction":"FALL"},{"count":370,"reaction":"DIZZINESS"},{"count":365,"reaction":"NAUSEA"},{"count":355,"reaction":"ASTHENIA"},{"count":349,"reaction":"HEADACHE"},{"count":344,"reaction":"INSOMNIA"}],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL628"},"_approvalHistory":[{"date":"20010330","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"19970709","type":"ORIG","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20000216","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20000216","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"19980921","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"19980302","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20000707","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20000216","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20000828","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"19980206","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20011102","type":"SUPPL","sponsor":"ANI PHARMS","applicationNumber":"ANDA074878"},{"date":"20150731","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20010618","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20010618","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20170329","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20010618","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20150731","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20150731","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"19990609","type":"ORIG","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20010618","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20010618","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20010618","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"20000124","type":"SUPPL","sponsor":"APOTEX","applicationNumber":"ANDA075191"},{"date":"19991103","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19990722","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19980407","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19980226","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20201102","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20160121","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20051212","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19970708","type":"ORIG","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20000419","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19991103","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19991103","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19980825","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19980407","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20160121","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20070112","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"20040121","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"},{"date":"19991115","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA074425"}],"publicationCount":5076,"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Ani Pharms","Apotex","Bausch","Heritage","Impax Labs","Pliva","Rising","Upsher Smith Labs"],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"PENTOXIFYLLINE","genericName":"PENTOXIFYLLINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1984","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:38:08.002097+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}